Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Martek S&P MidCap

This article was originally published in The Tan Sheet

Executive Summary

Columbia, Md.-based firm will be added to Standard & Poor's MidCap 400 index after the close of trading March 1, Martek announces Feb. 25; the index covers roughly 7% of the U.S. equities market. CEO Henry Linsert says Martek's addition "should broaden the company's exposure to investors." Martek signed a license and supply agreement with Kellogg earlier this month (1"The Tan Sheet" Feb. 14, 2005, In Brief)...

You may also be interested in...

Martek/Kellogg agreement

Columbia, Md.-based firm announces a 15-year, non-exclusive docosahexaenoic acid (DHA) license and supply agreement with Kellogg Feb. 4, with the first DHA-fortified food product scheduled for launch in mid-2006. Kellogg will develop foods containing Martek's DHA and "must purchase, subject to certain exceptions, almost all of its DHA from Martek" for products in the U.S., as well as "display the Martek DHA logo on all product packages, print advertisements and certain other promotional materials." Martek has supply agreements with Mead Johnson and Nestle to provide DHA for infant formula...

QUOTED. 8 August 2020. Ashley Wittorf.

AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.

Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma. 





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts